Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo, Shimane, 693-8501, Japan.
Department of Radiology, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo, Shimane, 693-8501, Japan.
Langenbecks Arch Surg. 2021 May;406(3):917-926. doi: 10.1007/s00423-021-02147-3. Epub 2021 Mar 12.
The role of ligation of the portal venous branches to the caudate lobe (cPVL) as preparation for planned major hepatectomy is unclear. The aim of this study was to evaluate the efficacy of laparoscopic cPVL (Lap-cPVL) concomitant with transileocolic portal vein embolization of the right portal venous system (rTIPE), namely, Lap-cPVL/rTIPE, for planned right hemihepatectomy (rHx) in advanced hepatobiliary cancer patients.
Thirty-one patients who underwent rHx after rTIPE with/without Lap-cPVL between March 2013 and March 2020 were enrolled in this study. The Lap-cPVL was performed for the portal branches of the right caudate lobe.
Eight of the 31 patients underwent Lap-cPVL/rTIPE. The degree of hypertrophy was significantly increased in Lap-cPVL/rTIPE (19.3%, range 6.5-25.6%) as compared to rTIPE (7.2%, range - 1.1 to 21.2%) (p=0.027). The functional kinetic growth rate was also significantly increased in Lap-cPVL/rTIPE (5.40%, range 2.17-5.97) than that in rTIPE (1.85%, range - 0.22 to 6.45%) (p=0.046). Postoperative liver failure ≧ grade B occurred in 21.7% of patients in rTIPE, while there was no postoperative liver failure ≧ grade B in Lap-cPVL/rTIPE. Mortality rates were zero after rHx in this study.
Lap-cPVL/rTIPE is safe and provides an additional effect on liver hypertrophy in advanced hepatobiliary cancers.
作为计划进行的重大肝切除术的准备,结扎门脉分支至尾状叶(cPVL)的作用尚不清楚。本研究旨在评估腹腔镜下尾状叶门静脉分支结扎(Lap-cPVL)联合右门静脉系统经回结肠间门静脉栓塞术(rTIPE),即 Lap-cPVL/rTIPE,在晚期肝胆管癌患者中计划行右半肝切除术(rHx)的疗效。
本研究纳入了 2013 年 3 月至 2020 年 3 月期间接受 rTIPE 联合/不联合 Lap-cPVL 后行 rHx 的 31 例患者。Lap-cPVL 用于右尾状叶的门静脉分支。
31 例患者中有 8 例行 Lap-cPVL/rTIPE。与 rTIPE(7.2%,范围-1.1 至 21.2%)相比,Lap-cPVL/rTIPE 的肝增生程度明显增加(19.3%,范围 6.5-25.6%)(p=0.027)。Lap-cPVL/rTIPE 的功能动力学生长率(5.40%,范围 2.17-5.97)也明显高于 rTIPE(1.85%,范围-0.22 至 6.45%)(p=0.046)。rTIPE 组术后发生肝衰竭≧B 级的患者占 21.7%,而 Lap-cPVL/rTIPE 组无术后肝衰竭≧B 级患者。本研究中 rHx 后无死亡病例。
Lap-cPVL/rTIPE 安全且能在晚期肝胆管癌中为肝增生提供附加作用。